A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
Latest Information Update: 30 May 2025
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms ACRUE
- Sponsors AstraZeneca
Most Recent Events
- 26 Jul 2024 Planned End Date changed from 29 Sep 2027 to 24 Aug 2027.
- 26 Jul 2024 Planned primary completion date changed from 29 Sep 2027 to 24 Aug 2027.
- 26 Jul 2024 Status changed from not yet recruiting to recruiting.